Multicellular contractility contributes to the emergence of mesothelioma nodules.
Actins
/ metabolism
Amides
/ pharmacology
Animals
Cell Count
Cell Line, Tumor
Heterocyclic Compounds, 4 or More Rings
/ pharmacology
Humans
Male
Mesothelioma, Malignant
/ metabolism
Mice, SCID
Myosins
/ metabolism
Pyridines
/ pharmacology
Stochastic Processes
Time-Lapse Imaging
Xenograft Model Antitumor Assays
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 11 2020
18 11 2020
Historique:
received:
26
05
2020
accepted:
29
09
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
23
4
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) has an overall poor prognosis and unsatisfactory treatment options. MPM nodules, protruding into the pleural cavity may have growth and spreading dynamics distinct that of other solid tumors. We demonstrate that multicellular aggregates can develop spontaneously in the majority of tested MPM cell lines when cultured at high cell density. Surprisingly, the nodule-like aggregates do not arise by excessive local cell proliferation, but by myosin II-driven cell contractility. Prominent actin cables, spanning several cells, are abundant both in cultured aggregates and in MPM surgical specimens. We propose a computational model for in vitro MPM nodule development. Such a self-tensioned Maxwell fluid exhibits a pattern-forming instability that was studied by analytical tools and computer simulations. Altogether, our findings may underline a rational for targeting the actomyosin system in MPM.
Identifiants
pubmed: 33208866
doi: 10.1038/s41598-020-76641-x
pii: 10.1038/s41598-020-76641-x
pmc: PMC7675981
doi:
Substances chimiques
Actins
0
Amides
0
Heterocyclic Compounds, 4 or More Rings
0
Pyridines
0
Y 27632
138381-45-0
blebbistatin
20WC4J7CQ6
Myosins
EC 3.6.4.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
20114Références
J Biol Chem. 2011 Oct 7;286(40):34858-71
pubmed: 21828044
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
J Math Biol. 1983;17(1):125-9
pubmed: 6875405
Science. 2003 Mar 14;299(5613):1743-7
pubmed: 12637748
Acta Biotheor. 1996 Nov;44(3-4):271-82
pubmed: 8953213
Nature. 2009 Jan 22;457(7228):495-9
pubmed: 19029882
Biophys J. 2004 Nov;87(5):3470-8
pubmed: 15347595
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
Oncotarget. 2015 Mar 20;6(8):6251-66
pubmed: 25749040
Development. 2014 May;141(10):1987-98
pubmed: 24803648
Oncogene. 2010 May 6;29(18):2724-38
pubmed: 20208566
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1943-8
pubmed: 21245302
Biophys J. 2014 Dec 2;107(11):2652-61
pubmed: 25468344
Science. 2012 Oct 12;338(6104):253-6
pubmed: 22923438
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Dev Cell. 2012 Jan 17;22(1):104-15
pubmed: 22169071
Pathol Res Pract. 2016 Oct;212(10):886-892
pubmed: 27485167
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):75-87
pubmed: 11033298
Clin Cancer Res. 2020 Jul 15;26(14):3819-3830
pubmed: 32317288
Cell Death Dis. 2019 Jan 25;10(2):58
pubmed: 30683844
J Biol Chem. 2004 Aug 20;279(34):35557-63
pubmed: 15205456
Phys Rev Lett. 2011 Jan 14;106(2):028103
pubmed: 21405254
J Embryol Exp Morphol. 1983 Dec;78:83-125
pubmed: 6663234
Cancer Res. 2009 Nov 15;69(22):8742-51
pubmed: 19887617
Sci Rep. 2017 Sep 4;7(1):10404
pubmed: 28871207
J Pathol. 2015 Oct;237(2):203-14
pubmed: 26011651
Nature. 1997 Oct 30;389(6654):990-4
pubmed: 9353125
Acta Pharmacol Sin. 2018 Oct;39(10):1590-1603
pubmed: 29620051
Dev Dyn. 2008 Jul;237(7):1826-36
pubmed: 18570249
Phys Biol. 2014 Dec 15;12(1):016005
pubmed: 25502910
PLoS One. 2012;7(2):e31711
pubmed: 22359617
BMC Cancer. 2006 May 17;6:130
pubmed: 16704740
Science. 1978 May 12;200(4342):618-27
pubmed: 347575
Biophys J. 2006 Oct 1;91(7):2708-16
pubmed: 16829558
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207
pubmed: 11033306
Prog Biophys Mol Biol. 2014 Aug;115(2-3):76-92
pubmed: 25008017
Cancer Cell. 2012 Mar 20;21(3):283-96
pubmed: 22439924
Anticancer Res. 2009 Jan;29(1):119-23
pubmed: 19331140
Oncotarget. 2017 Mar 28;8(13):21418-21428
pubmed: 28199964
Melanoma Res. 2003 Oct;13(5):483-92
pubmed: 14512790
PLoS One. 2018 Sep 4;13(9):e0203203
pubmed: 30180178
Nature. 2004 Jun 10;429(6992):667-71
pubmed: 15190355
F1000Res. 2016 Apr 29;5:
pubmed: 27158478
PLoS Comput Biol. 2017 Nov 17;13(11):e1005818
pubmed: 29149169
Dev Biol. 1982 Apr;90(2):383-98
pubmed: 7075867
Exp Cell Res. 2013 Dec 10;319(20):3094-103
pubmed: 23973668
Ann Biomed Eng. 2005 Jun;33(6):854-65
pubmed: 16078625
Nat Commun. 2019 Mar 12;10(1):1186
pubmed: 30862791
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Biophys J. 2008 Dec 15;95(12):6044-51
pubmed: 18775964
Oncogene. 2012 Sep 27;31(39):4279-89
pubmed: 22249252
J Pathol. 2015 Feb;235(3):381-3
pubmed: 25351454
J Cell Biol. 2002 Jun 10;157(6):1083-91
pubmed: 12058022
PLoS Comput Biol. 2019 Oct 25;15(10):e1007431
pubmed: 31652274
Nat Mater. 2011 Jun;10(6):469-75
pubmed: 21602808
Oncol Rep. 2010 Mar;23(3):861-7
pubmed: 20127030